基于美国与日本生物制品数据保护期限设置方法对比分析研究

姚雪芳, 丁锦希, 李鹏辉

中国药学杂志 ›› 2017, Vol. 52 ›› Issue (10) : 891-896.

PDF(1360 KB)
PDF(1360 KB)
中国药学杂志 ›› 2017, Vol. 52 ›› Issue (10) : 891-896. DOI: 10.11669/cpj.2017.10.018
论著

基于美国与日本生物制品数据保护期限设置方法对比分析研究

  • 姚雪芳, 丁锦希*, 李鹏辉
作者信息 +

Setting Method Study of Data Protection Period for Biologics——Based on the Comparative Analysis of American and Japanese Methods

  • YAO Xue-fang, DING Jin-xi*, LI Peng-hui
Author information +
文章历史 +

摘要

目的 比较研究美国及日本生物制品数据保护期限设置方法,为我国未来制度设置提供参考。方法 通过方法介绍和特点分析,对比评价美国盈亏平衡模型方法和日本风险管理评估方法。结果 美国和日本的两种设置方法分别侧重于不同的制度宗旨,我国设置方法的选择需要结合测算方法的可实施性和我国未来的政策目标与国情综合考量。结论 目前及未来较长一段时间,我国医药产业仍处于“仿创结合”阶段,药品安全问题仍为核心任务。因此,建议我国未来在设置方法上,应以风险评估管理方法为主,盈亏平衡模型方法为辅,综合设置生物制品数据保护期限,从而有效发挥激励创新、改善创新药可获得性、强化药品安全监控3大政策效应。

Abstract

OBJECTIVE To compare the setting methods for biologics data protection period between America and Japan, in order to provide suggestions for China. METHODS We made a contrastive study of American “break even” model and Japanese “risk management evaluation” model by using method introduction and characteristic analysis. RESULTS The two setting methods in the US and Japan focus on different system objectives, respectively. The Chinese choice of setting method needs to combine the feasibility of setting methods and the national conditions and policy goals for comprehensive consideration. CONCLUSION At present and the future for a long time, China's pharmaceutical industry is still in the “imitation to innovation” stage, and drug safety issues remain the core task. Therefore, the period of biologics data protection should be rationally set up by using “risk management evaluation” model as the base, “break even” model as supplement, so as to bring the three policy effects such as innovation incentive, the improvement of innovative drugs availability and strengthening the drug post-market safety monitoring.

关键词

生物制品 / 数据保护期限 / 设置方法 / 美国 / 日本

Key words

biologics / data protection period / setting method / the US / Japan

引用本文

导出引用
姚雪芳, 丁锦希, 李鹏辉. 基于美国与日本生物制品数据保护期限设置方法对比分析研究[J]. 中国药学杂志, 2017, 52(10): 891-896 https://doi.org/10.11669/cpj.2017.10.018
YAO Xue-fang, DING Jin-xi, LI Peng-hui. Setting Method Study of Data Protection Period for Biologics——Based on the Comparative Analysis of American and Japanese Methods[J]. Chinese Pharmaceutical Journal, 2017, 52(10): 891-896 https://doi.org/10.11669/cpj.2017.10.018
中图分类号: R951   

参考文献

[1] GAO C Y, XIE S M, BAI Y, et al.Considerations on clinical study of biosimilars[J].Chin Pharm J(中国药学杂志),2015, 50(6):494-495.
[2] YANG L, CHENY W, LIANG Y, et al. Development of pharmaceutical data protection in the world[J].Chin J New Drugs(中国新药杂志), 2011,20(9):766-770.
[3] TPP Full Text, CHAPTER 18 INTELLECTUAL PROPERTY [EB/OL]. 2016-10-28. https://ustr.gov/sites/default/files/TPP-Final-Text-Intellectual-Property.pdf
[4] GRABOWSKIH G. Follow-on biologics:data exclusivity and the balance between innovation and competition[J]. Nat Rev Drug Discov, 2008,7(6):479-488.
[5] DIMASI J A, GRABOWSKI H G. The cost of biopharmaceutical R&D:is biotech different? [J]. Manage Decis Econ, 2007, 28(4-5):469-479.
[6] GRABOWSKIH G, LONG G, MORTIMER R. Data exclusivity for biologics[J]. Nat Rev Drug Discov, 2011, 10(1):15-16.
[7] Annual Health, Labour and Welfare Report 2011-2012 [EB/OL]. 2016-9-10. http://www.mhlw.go.jp/english/wp/wp-hw6/dl/02e. pdf
[8] JPMA. Pharmaceutical Administration and Regulations in Japan [EB/OL]. 2015-12-20. http://www.jpma.or.jp/english/parj/pdf/2015.pdf
[9] YU M. The Law of Torts in Japan(日本侵权行为法)[M]. Beijing:Law Press, 1998:321.
[10] DING J X, TOU J Y, YAN J Z. Safety monitoring of pharmaceutical test data protection in Japan and itsimplication—an empirical study of post-marketing risk management on sertraline [J]. Chin J New Drugs Clin Rem(中国新药与临床杂志), 2015, 34(8):592-597.
[11] DING J X, REN H Y, YAO X F. Data protection provisions for biologics in TPP and policy orientation in China[J].Shanghai Med Pharm J(上海医药), 2016, 37(17):56-57.
[12] DING J X, LI Y, WANG Y W. Comparative analysis of the innovative drug monitoring periodsystem between China and Japan[J]. Chin J New Drugs(中国新药杂志), 2012,15(16):1840-1845.

基金

国家社会科学基金项目《TRIPS协议框架下中国药品试验数据保护制度研究》(13BFX120);国家食品药品监督管理总局2016年委托课题《新形势下药品数据保护与专利链接制度评估与设计》的阶段性成果
PDF(1360 KB)

Accesses

Citation

Detail

段落导航
相关文章

/